Targeting eosinophil extracellular traps in asthma: a new axis for biologic intervention

Extract Asthma is a heterogeneous chronic airway disease in which eosinophilic inflammation remains a dominant and clinically actionable endotype. Over the past decade, biologics targeting interleukin (IL)-5, IL-5Rα, IL-4Rα and IgE have transformed the management of severe type 2 asthma, firmly establishing eosinophils as central drivers of disease activity [1–4].